INDIVIOR PLC

The following table sets forth the names and positions of the members of our Board as of the date of this annual report. Except as otherwise indicated, the business address of each of the directors is 234 Bath Road, Slough, Berkshire SL1 4EE, United Kingdom.

(1) The dates listed represent the end of the respective Director's term of office on the Board per their letter of appointment. All directors are subject to election or re-election by shareholders at each Annual General Meeting.

(2) The letters of appointment of Drs. Wheadon and Humphreys and Messrs. Ciaffoni, Ninivaggi, and Schriesheim do not contain a fixed end to their term of office on the Board.

(3) See "Item 9B-Other Information" at page 161.

(4) Per his employment with the Company, Mr. Crossley serves at the request of the Board and may be removed at any time. His business address is 10710 Midlothian Turnpike, Suite 125, North Chesterfield, VA, 23235, United States.

Dr. David Wheadon, age 67, has served as Chair of the Board since January 2025 and as a non-executive director since June 2024. The Board values Dr. Wheadon's extensive experience in the pharmaceutical industry, including executive responsibility for regulatory affairs, patient safety, quality, research, and advocacy. Dr. Wheadon previously served as SVP of global regulatory affairs, patient safety, and quality assurance at AstraZeneca Plc from December 2014 to July 2019. Prior to that, he was EVP-Research & Advocacy at Juvenile Diabetes Research Foundation International Inc. from May 2013 to December 2014, SVP-Scientific & Regulatory Affairs at Pharmaceutical Research and Manufacturers of America (PhRMA) from January 2009 to May 2013, and VP-Global Pharmaceutical Regulatory & Medical Science and Group VP-Global Pharmaceutical Regulatory Affairs at Abbott Laboratories from 2005 to 2009. Dr. Wheadon also held senior regulatory and clinical development leadership positions at GlaxoSmithKline Plc and Eli Lilly and Company. He is a non-executive director of Sotera Health Company (NASDAQ: SHC), Vaxart, Inc. (NASDAQ: VXRT), where he serves as Chair of the Compensation Committee, ConnectiveRx, and Seaport Therapeutics. He also serves as a member of the Board of Trustees of Mount Sinai Health System. Dr. Wheadon received his MD from Johns Hopkins University School of Medicine and an AB in Biology from Harvard University, and completed his postdoctoral training in Psychiatry at Tufts/New England Medical Center.

Mark Crossley—Chief Executive Officer. See biography at page 162.

Juliet Thompson, age 58, has served as an independent non-executive director since March 2021 and as Lead Independent Director since October 2023. Ms. Thompson has over 30 years of finance, banking, and board experience with significant focus on the healthcare sector. The Board values Ms. Thompson's experience as a proven FTSE 250 audit chair and a former investment banker who has spent her career advising pharmaceutical and biotech companies. Ms. Thompson currently serves as a non-executive director and Chair of the Audit Committees of Novacyt S.A., OrganOx Limited, and ANGLE plc. From 2013 until her retirement in in 2015, Ms. Thompson led the life sciences and clean tech teams at Stifel Financial Corp. where she advised CEOs and CFOs in the healthcare sector. Prior to joining Stifel, from 2003 to

2013, Ms. Thompson was employed by Nomura Code and advised companies in the healthcare and clean tech sectors on their financing and strategic options. She worked on over 50 transactions including IPO’s, secondary offerings, private placements, and M&A. She played a leading role in setting up Code Securities, which was acquired by Nomura (becoming Nomura Code) but remained independent. Previously, she served on the boards of GI Dynamics, Inc., a Boston-based medical device company developing products for patients with type 2 diabetes and obesity, from 2017 to 2020, and Vectura plc from 2017 to 2021. Ms. Thompson holds a BSc in Economics from the University of Bristol and qualified as a Chartered Accountant and holds an ACA from the Association of Chartered Certified Accountants.

Peter Bains, age 67, has served as an independent non-executive director since August 2019. He brings international experience across the biopharma industry spectrum and a deep commercial understanding of sustained delivery coupled with investment appraisal and contracting skills. The Board values Mr. Bains' experience in understanding the risks and opportunities present in these industries. He currently serves as Group CEO (a non-Board appointment) of Biocon Limited, an Indian public company focused on contract services and generics. Mr. Bains is Non-Executive Chair of ILC Therapeutics, a private U.K.-based biotechnology company and pioneer in the discovery and development of hybrid interferon drugs, and is a non-executive director of both Apterna Limited and MiNA Therapeutics Limited. Mr. Bains has over 30 years of experience in the pharmaceutical and biotechnology industries, including a 23-year career at GlaxoSmithKline, where he held numerous senior operational and strategic roles. He also served as CEO of Sosei Group Corporation, a Tokyo-listed biotech company, from 2010 to 2018, as CEO of Syngene International, which he successfully took public on the Mumbai Exchange, from 2010 to 2016, and as a member of the board of Mereo BioPharma Group plc (NASDAQ: MREO), a public biopharmaceutical company focused on innovative therapeutics in both oncology and rare diseases, from 2015 to 2021. Mr. Bains holds a BSc (Combined Honours) in Physiology/Zoology from Sheffield University.

Joe Ciaffoni, age 53, has served as an independent non-executive director since December 2024. He is an accomplished public company CEO with over 30 years of experience in pharmaceuticals and biotech, serving global and U.S. organizations of all sizes. The Board values Mr. Ciaffoni's track record of success at the intersection of strategy and operations across diverse models and therapeutic areas, including launching successful products, optimizing commercial operations, and enhancing patient access to important therapies. He previously served as President and CEO and on the board of Collegium Pharmaceuticals, Inc. (NASDAQ: COLL) from 2018 to 2024, having joined as EVP and COO in 2017. Prior to joining Collegium, Mr. Ciaffoni served as President, U.S. Branded Pharmaceuticals at Endo International plc, held various positions of increasing responsibility at Biogen (including SVP, Global Speciality Medicines Group), and served as EVP and COO of Shionogi Inc. and President of Shionogi Pharmaceuticals. He also previously served in various commercial roles at Schering-Plough (now Merck), Sanofi-Synthelabo (now Sanofi), and Novartis. Mr. Ciaffoni holds a BA in Communications and an MBA from Rutgers University.

Dr. Keith Humphreys, age 58, has served as an independent non-executive director since November 2023. The Board values Dr. Humphreys' over 30 years of experience in the field of clinical psychology and substance use disorders, having been awarded an Officer of the Order of the British Empire (OBE) in September 2022 for his services to science and policy on addiction. Dr. Humphreys currently serves as Esther Ting Memorial Professor in the Department of Psychiatry and Behavioral Sciences at Stanford University. He was previously a Senior Policy Advisor in the White House Office of National Drug Control Policy in the Obama Administration and is an Honorary Professor of Psychiatry at the Institute of Psychiatry, King’s College, London. Dr. Humphreys holds a BA in Psychology from Michigan State University and an AM in Clinical/Community Psychology and PhD in Psychology from the University of Illinois.

Jo LeCouilliard, age 61, has served as an independent non-executive director since March 2021 and as a Designated Non-Executive Director for Workforce Engagement since October 2023. The Board values Ms. LeCouilliard's experience as a healthcare industry veteran with over 25 years of healthcare management experience gained in Europe, the U.S., and Asia. Much of her career has been in pharmaceuticals at GlaxoSmithKline where, amongst other roles, she headed the U.S. vaccines business and Asia Pacific Pharmaceuticals business and led a program to modernize the commercial model. Ms. LeCouilliard was previously COO at the BMI group of private hospitals in the U.K. She currently serves as a non-executive director and Chair of the Remuneration & Nominations Committee at the Italian-listed pharmaceutical company Recordati S.p.A., and as a member of the board of directors of Washington Topco Ltd, the holding company of GlobalData Healthcare. She has previously served as a non-executive director and Chair of the Board at the U.K.-listed Alliance Pharma plc, as a non-executive director and Chair of the Audit & Risk Committee at the U.K.-listed Niox Group PLC (previously Circassia Group plc), and as a non-executive director at Frimley Park NHS Foundation Trust in the U.K., at Cello Health PLC, and at the Duke NUS Medical School in Singapore. Ms. LeCouilliard is a Chartered Accountant holding an ACA from the Institute of Chartered Accountants in England & Wales and holds a Masters in Natural Sciences from the University of Cambridge.

Daniel Ninivaggi, age 60, has served as an independent non-executive director since January 2025. The Board values Mr. Ninivaggi’s significant public company experience as a director and executive, his strong background in operations and capital allocation, and his legal and finance expertise. Mr. Ninivaggi currently serves as Non-Executive Chairman and Chair of the Finance Committee of Garrett Motion Inc. (NASDAQ: GTX), a global supplier of turbochargers and other powertrain components to light vehicle, commercial vehicle, and industrial end markets. From August 2021 until March 2024, he served as CEO and subsequently Executive Chairman of Lordstown Motors Corp. (formerly NASDAQ: RIDE), an electric vehicle automaker. Prior to that, Mr. Ninivaggi served as President and CEO of Icahn Enterprises L.P. (NASDAQ: IEP), the principal investment vehicle of Carl Icahn; as Co-CEO of Federal-Mogul Holdings Corp. (a public-company subsidiary of IEP now part of Apollo Global Management); and as CEO of Icahn Automotive Group, LLC and a Managing Director of IEP. Prior to joining IEP, he spent six years at Lear Corporation (NYSE: LEA), holding various senior executive positions. In addition to those positions noted above, Mr. Ninivaggi has served as a director of numerous other public and private companies, including Hertz Global Holdings, Inc., Navistar International Corporation, Icahn Enterprises G.P. Inc. (the general partner of Icahn Enterprises), CVR Energy Inc., XO Holdings, Tropicana Entertainment Inc., Motorola Mobility Holdings Inc., and CIT Group, Inc. Mr. Ninivaggi began his career at Skadden, Arps, Slate, Meagher & Flom LLP before joining Winston & Strawn LLP, where he became partner specializing in corporate law. He holds a BA from Columbia University, an MBA from the University of Chicago Graduate School of Business, and a JD degree (with distinction) from Stanford University School of Law.

Barbara Ryan, age 65, has served as an independent non-executive director since June 2022. She was a Wall Street sell-side research analyst covering the U.S. Large Cap Pharmaceutical Industry for more than 30 years before founding Barbara Ryan Advisors, a capital markets and communications firm, in 2012. The Board values Ms. Ryan's deep experience in equity and debt financings, M&A, valuation, SEC reporting, financial analysis, and corporate strategy across a broad range of life sciences companies. Ms. Ryan is the Founder of Fabulous Pharma Females, a non-profit organization whose mission is to advance women in the biopharmaceutical industry. She is a Senior Advisor at Ernst & Young (a part-time role) and a non-executive director of INVO Bioscience, Inc. (NASDAQ: INVO), MiNK Therapeutics, Inc. (NASDAQ: INKT), serving as Chair of the Audit Committee, and Azitra, Inc. (NYSE: AZTR), serving as Chair of the Compensation Committee, OcuTerra Therapeutics, and Safecor Health.

Robert Schriesheim, age 64, has served as an independent non-executive director since December 2024. The Board values Mr. Schriesheim's expertise in corporate finance, strategy, and capital markets, as well as his knowledge in public company governance and board practices of other corporations. He is chairman of Truax Partners LLC and leads large, complex transformations in partnership with Boards, CEOs, and institutional investors as an investor and director. Mr. Schriesheim has served on 12 public boards ranging from under $1 billion in revenue to Fortune 500, including as chairman, and has served as CFO of four public companies varying in revenue from $1 billion to $40 billion. He also serves as an Adjunct Associate Professor of Finance with a focus on corporate governance at The University of Chicago Booth School of Business. Mr. Schriesheim previously served as CFO of Sears Holdings, Hewitt Associates, and Lawson Software, and held executive roles at seed venture firm ARCH Development Partners, LLC, Global TeleSystems, SBC Equity Partners, Ameritech, AC Nielsen, and Brooke Group Ltd. Mr. Schriesheim has been a director of Skyworks Solutions, Inc. (NASDAQ: SWKS) since 2006 and Houlihan Lokey, Inc. (NYSE: HLI) since 2015, serving as Lead Independent Director and as Chair of the Audit Committee. Effective March 1, 2025, he will join the board of Alight, Inc. (NYSE: ALIT). Mr. Schriesheim previously served on a number of other public boards including Frontier Communications (as Chair of the Finance Committee overseeing the company during its Chapter 11 proceedings), NII Holdings, Forest City Reality Trust (Chair of the Audit Committee), Lawson Software, Co-Chairman of MSC Software, and Dobson Communications. Mr. Schriesheim earned an AB in Chemistry from Princeton University and an MBA from the University of Chicago Booth School of Business.

Mark Stejbach, age 61, has served as an independent non-executive director since March 2021 and as a Designated Non-Executive Director for Workforce Engagement since October 2023. The Board values Mr. Stejbach's over 35 years of experience in biotech and pharmaceuticals, including senior roles in a broad range of commercial functions including marketing, sales, economic affairs, managed care, and finance. Mr. Stejbach most recently served as SVP & Chief Commercial Officer at Alkermes plc, a publicly traded global biopharmaceutical company focused on development and commercialization of addiction and schizophrenia treatments. Prior to his role at Alkermes, Mr. Stejbach served as the Chief Commercial Officer at Tengion, Inc. from 2008 to 2012 and previously held senior positions at Merck and Biogen. He also previously served as Senior Commercial Advisor to EIP Pharma Inc., a private company advancing CNS-focused therapeutics to benefit patients with neurodegenerative diseases. Mr. Stejbach currently serves as a director of Nirsum Laboratories, Inc. and previously served as a non-executive director of Flexion Therapeutics, Inc. (NASDAQ: FLXN), which marketed a “buy-and-bill” LAI for the treatment of osteoarthritis, from 2016 until its acquisition in 2021. Mr. Stejbach holds an MBA from the Wharton School, University of Pennsylvania and a BS in mathematics from Virginia Tech.